Examining the Impact of Age on Chemotherapy Effectiveness among Lung Cancer Patients
DOI:
https://doi.org/10.56294/hl2025603Keywords:
Lung Cancer Patients, Chemotherapy, age, descriptive statisticsAbstract
Introduction: Lung cancer remains a prevalent type of cancer that affects many people and causes their death. Variations in chemotherapy effectiveness among different age groups of lung cancer patients can influence treatment outcomes, necessitating an investigation into age-specific responses to chemotherapy. The research aims to examine the impact of age on chemotherapy effectiveness among lung cancer (LC) patients, focusing on overall survival time, response rate, and comorbidity scores across different age categories.
Methods: A total of 300 lung cancer patients undergoing chemotherapy were surveyed. Patients were divided into three age groups: ≤ 50 years, 50–69 years, and ≥ 70 years. Data analysis was performed using SPSS 25, employing descriptive statistics, regression analysis, correlation analysis, and ANOVA to evaluate factors affecting chemotherapy outcomes.
Result: Descriptive statistics revealed the highest average survival time of 36 months with a response rate of 90%. Regression analysis identified an intercept of 62.00, with negative coefficients associated with increasing age and advanced disease stage. Correlation analysis showed a positive correlation of 0.45 between response rate and survival time. ANOVA indicated an average response rate of 67.8% among patients aged below 50, suggesting a potential benefit in tailored treatment strategies for younger patients.
Conclusion: These results support the treatment of patients with lung cancer, according to their age in an attempt to improve the outcomes of chemotherapy sessions. The research highlights a need for further research into age-related factors that influence treatment outcomes, emphasizing personalized approaches for improved patient care.
References
1.Ureshino H, Shindo T, Kimura S. Role of cancer immunology in chronic myelogenous leukemia. Leukemia research. 2020 Jan 1;88:106273. https://doi.org/10.1016/j.leukres.2019.106273
2. Eusebi LH, Telese A, Marasco G, Bazzoli F, Zagari RM. Gastric cancer prevention strategies: a global perspective. Journal of gastroenterology and hepatology. 2020 Sep;35(9):1495-502. 10.1111/jgh.15037
3. Kumar M, Sarma DK, Shubham S, Kumawat M, Verma V, Prakash A, Tiwari R. Environmental endocrine-disrupting chemical exposure: role in non-communicable diseases. Frontiers in public health. 2020 Sep 24; 8:553850.https://doi.org/10.3389/fpubh.2020.553850
4. Bilotta MT, Antignani A, Fitzgerald DJ. Managing the TME to improve the efficacy of cancer therapy. Frontiers in immunology. 2022 Oct 20; 13:954992.https://doi.org/10.3389/fimmu.2022.954992
5. Damluji AA, Forman DE, Van Diepen S, Alexander KP, Page RL, Hummel SL, Menon V, Katz JN, Albert NM, Afilalo J, Cohen MG. Older adults in the cardiac intensive care unit: factoring geriatric syndromes in the management, prognosis, and process of care: a scientific statement from the American Heart Association. Circulation. 2020 Jan 14;141(2):e6-32.https://doi.org/10.1161/CIR.0000000000000741
6. Akinoso-Imran AQ, O'Rorke M, Kee F, Jordao H, Walls G, Bannon FJ. Surgical under-treatment of older adult patients with cancer: A systematic review and meta-analysis. Journal of geriatric oncology. 2022 May 1;13(4):398-409.https://doi.org/10.1016/j.jgo.2021.11.004
7. Gomes F, Wong M, Battisti NM, Kordbacheh T, Kiderlen M, Greystoke A, Luciani A. Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper. British Journal of Cancer. 2020 Sep 15;123(6):874-84.https://doi.org/10.1038/s41416-020-0986-4
8.Cui Y, Shi X, Wang S, Qin Y, Wang B, Che X, Lei M. Machine learning approaches for prediction of early death among lung cancer patients with bone metastases using routine clinical characteristics: an analysis of 19,887 patients. Frontiers in Public Health. 2022 Oct 6;10:1019168.https://doi.org/10.3389/fpubh.2022.1019168
9. Kuang PP, Li N, Liu Z, Sun TY, Wang SQ, Hu J, Ou W, Wang SY. Circulating tumor DNA analyses as a potential marker of recurrence and effectiveness of adjuvant chemotherapy for resected non-small-cell lung cancer. Frontiers in oncology. 2021 Feb 15; 10:595650.https://doi.org/10.3389/fonc.2020.595650
10. Crawford J, Denduluri N, Patt D, Jiao X, Morrow PK, Garcia J, Barron R, Lyman GH. Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. Supportive Care in Cancer. 2020 Feb;28:925-32.https://doi.org/10.1007/s00520-019-04875-1, https://doi.org/10.1007/s00520-019-04875-1
11. Oudkerk M, Liu S, Heuvelmans MA, Walter JE, Field JK. Lung cancer LDCT screening and mortality reduction—evidence, pitfalls and future perspectives. Nature reviews Clinical oncology. 2021 Mar;18(3):135-51. https://doi.org/10.1038/s41571-020-00432-6
12. Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI. Immunotherapy in lung cancer: current landscape and future directions. Frontiers in immunology. 2022 Feb 9;13:823618. https://doi.org/10.3389/fimmu.2022.823618
13. Drilon A, Duruisseaux M, Han JY, Ito M, Falcon C, Yang SR, Murciano-Goroff YR, Chen H, Okada M, Molina MA, Wislez M. Clinicopathologic features and response to therapy of NRG1 fusion–driven lung cancers: The eNRGy1 global multicenter registry. Journal of Clinical Oncology. 2021 Sep 1;39(25):2791-80210. http://ascopubs.org/doi/full/10.1200/JCO.20.03307
14. Gourzoulidis G, Zisimopoulou O, Boubouchairopoulou N, Michailidi C, Lowry C, Tzanetakos C, Kourlaba G. Cost-effectiveness analysis of lorlatinib in patients previously treated with anaplastic lymphoma kinase inhibitors for non-small cell lung cancer in Greece. Journal of Health Economics and Outcomes Research. 2022 Feb 17;9(1):50. 10.1007/s10330-022-0620-0
15. Okada N, Matsuoka R, Sakurada T, Goda M, Chuma M, Yagi K, Zamami Y, Nishioka Y, Ishizawa K. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study. Scientific reports. 2020 Aug 13;10(1):13773. https://doi.org/10.1038/s41598-020-70743-2
16. Sui Y, Wang T, Wang X. The impact of WeChat app-based education and rehabilitation program on anxiety, depression, quality of life, loss of follow-up and survival in non-small cell lung cancer patients who underwent surgical resection. European Journal of Oncology Nursing. 2020 Apr 1;45:101707. https://doi.org/10.1016/j.ejon.2019.101707
17. Mino-Kenudson M, Schalper K, Cooper W, Dacic S, Hirsch FR, Jain D, Lopez-Rios F, Tsao MS, Yatabe Y, Beasley MB, Yu H. Predictive biomarkers for immunotherapy in lung cancer: perspective from the international association for the study of lung cancer pathology committee. Journal of Thoracic Oncology. 2022 Dec 1;17(12):1335-54. https://doi.org/10.1016/j.jtho.2022.09.109
18. Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, Zenke Y, Lee KH, Wang Q, Navarro A, Bernabe R. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. New England Journal of Medicine. 2024 Oct 10;391(14):1313-27. 10.1056/NEJMoa2404873
19. Chang JY, Verma V, Weichselbaum RR. Reconciling the discrepancies in randomized data of combining immunotherapy and radiation therapy: Not all radiotherapy is created equal. European Journal of Cancer. 2024 Apr 1;201:113972 https://doi.org/10.1016/j.ejca.2024.113972
20. Zheng Z, Zhu H, Fang L, Cai H. Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer. Frontiers in Pharmacology. 2022 Sep 12;13:996914. https://doi.org/10.3389/fphar.2022.996914.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Parthkumar Devmurari , Vasanthi V, Lakshya Swarup, Lokesh Verma, Vundela Swathi, Renuka Devi MR (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
